1-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone | 1431323-75-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone
• 英文别名: 1-[4-Chloro-2-(methylthio)-5-pyrimidinyl]-2-(2,6-dichlorophenyl)ethanone；1-(4-chloro-2-methylsulfanylpyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone
• CAS: 1431323-75-9
• 化学式: C₁₃H₉Cl₃N₂OS
• 分子量: 347.652
• InChiKey: OMVAUGDDBVALBW-UHFFFAOYSA-N

物化性质

• 沸点：
  461.7±40.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  68.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone 在 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 异丙醇 、 乙腈 为溶剂， 反应 26.0h， 生成 6-(2,6-dichlorophenyl)-8-ethyl-2-((2'-methyl-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one
  参考文献：
  名称：

  Investigation of biaryl heterocycles as inhibitors of Wee1 kinase

  摘要：

  In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure - activity exploration of substituents at C-8 or N-8 which were used for tuning compound properties and to improve compound profiles. The lead molecule 33 demonstrated a desirable pharmacokinetic profile and potentiated the anti-proliferative activity of irinotecan in vivo when dosed orally in the human breast MX-1 xenograft model.

  DOI：

  10.1016/j.bmcl.2019.04.017
• 作为产物：
  描述：

  4-羟基-2-(甲硫基)嘧啶-5-羧酸 在 氯化亚砜 、 copper(l) cyanide 、 N,N-二甲基甲酰胺 、 lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 4.75h， 生成 1-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone
  参考文献：
  名称：

  Investigation of biaryl heterocycles as inhibitors of Wee1 kinase

  摘要：

  In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure - activity exploration of substituents at C-8 or N-8 which were used for tuning compound properties and to improve compound profiles. The lead molecule 33 demonstrated a desirable pharmacokinetic profile and potentiated the anti-proliferative activity of irinotecan in vivo when dosed orally in the human breast MX-1 xenograft model.

  DOI：

  10.1016/j.bmcl.2019.04.017

文献信息

• PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20130102590A1

  公开（公告）日：2013-04-25

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式（I）的化合物或药用可接受的盐，其中R1、R2、R3、R4和B在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制wee-1等激酶，并治疗癌症等疾病的方法。
• US9181239B2
  申请人：——

  公开号：US9181239B2

  公开（公告）日：2015-11-10
• [EN] PYRIDOPYRIMIDINONE INHIBITORS OF KINASES<br/>[FR] COMPOSÉS DE PYRIDOPYRIMIDINONE INHIBITEURS DE KINASES
  申请人：ABBVIE INC

  公开号：WO2013059485A1

  公开（公告）日：2013-04-25

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.